Backed by a handful of prominent investors including the Gates Foundation, the startup is pursuing an approach it believes ...

The baby saved from a rare disease by a first-ever personalized gene fix has reached a big milestone, taking his first steps ahead of Christmas. KJ Muldoon is walking and getting ready to celebrate ...

A 10-month-old baby who sparked nationwide headlines after receiving a first-of-its kind gene-editing treatment was released ...

EXTON, PA, Aug. 14, 2025 (GLOBE NEWSWIRE) -- As the first wave of gene therapies for transfusion-dependent β-thalassemia (TDT) continues to roll out in the U.S., a new conversation is emerging within ...

A long-term, trust-based CDMO partnership can support cell and gene therapy developers from early process development through ...

A cutting-edge base-edited CAR T-cell therapy is opening a revolutionary new frontier for patients battling aggressive T-cell ...

Biotech Addition emerges with $100M from the Gates Foundation to develop next-generation gene therapies for chronic and rare diseases with a new approach The Silicon Review.

In the past three years, gene therapy has reshaped what's possible in hemophilia treatment for patients 18 and older. But a ...

Cellular Origins is a UK‑based company enabling scalable, factory‑led automation for cell and gene therapy manufacturing, and ...

Later-stage financing deals for cell and gene therapy companies reflects a broader derisking trend in the pharma industry.

The MarketWatch News Department was not involved in the creation of this content. EXTON, PA, Aug. 14, 2025 (GLOBE NEWSWIRE) -- As the first wave of gene therapies for transfusion-dependent ...